ReviewMolecular neurobiology2017
Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.
Review in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 60 citations in OpenAlex.
- Calcium Dysregulation Promotes Glioma Progression by Inhibiting STAT3 Degradation Through Blocking Chaperone-Mediated Autophagy.Journal of cellular and molecular medicine · 2026Article
- Nuclear transport of phosphorylated LanCL2 promotes invadopodia formation and tumor progression of glioblastoma by activating STAT3/Cortactin signaling.Journal of advanced research · 2025Article
- Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3/STAT3 signaling pathway.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Article
- Progress in Glioma Stem Cell Research.Cancers · 2023Review
- ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma.BMC cancer · 2023Article
- Zinc Finger E-Box Binding Homeobox Family: Non-Coding RNA and Epigenetic Regulation in Gliomas.Biomedicines · 2023Review
- Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition.International journal of molecular sciences · 2023Review
- Ruxolitinib-Loaded Imprinted Polymeric Drug Reservoir for the Local Management of Post-Surgical Residual Glioblastoma Cells.Polymers · 2023Article
- Glioblastoma management in low and middle-income countries; existing challenges and policy recommendations.Brain & spine · 2023Review
- Microglial Extracellular Vesicles as Modulators of Brain Microenvironment in Glioma.International journal of molecular sciences · 2022Review
- STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.Neuro-oncology · 2022Article
- Role of the circulatory interleukin-6 in the pathogenesis of gliomas: A systematic review.World journal of methodology · 2022Article
- Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment.Advanced drug delivery reviews · 2022Review
- Next Steps for Immunotherapy in Glioblastoma.Cancers · 2022Review
- The novel histone deacetylase inhibitor pracinostat suppresses the malignant phenotype in human glioma.Molecular biology reports · 2022Article
- Review
- Transcription Factors with Targeting Potential in Gliomas.International journal of molecular sciences · 2022Review
- Chromatin accessibility analysis identifies GSTM1 as a prognostic marker in human glioblastoma patients.Clinical epigenetics · 2021Article
- Noncoding RNAs involved in the STAT3 pathway in glioma.Cancer cell international · 2021Review
- UBE2D3 Activates SHP-2 Ubiquitination to Promote Glycolysis and Proliferation of GliomaFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signal transducer and activator of transcription 3 (STAT3) is aberrantly activated in glioblastoma and has been identified as a relevant therapeutic target in this disease and many other human cancers. After two decades of intensive research, there is not yet any approved STAT3-based glioma therapy. In addition to the canonical activation by tyrosine 705 phosphorylation, concordant reports described a potential therapeutic relevance of other post-translational modifications including mainly serine 727 phosphorylation. Such reports reinforce the need to refine the strategy of targeting STAT3 in each concerned disease. This review focuses on the role of serine 727 and tyrosine 705 phosphorylation of STAT3 in glioma. It explores their contribution to glial cell transformation and to the mechanisms that make glioma escape to both immune control and standard treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.